Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice
Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Five-week-o...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2010-09, Vol.16 (18), p.4595-4606 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4606 |
---|---|
container_issue | 18 |
container_start_page | 4595 |
container_title | Clinical cancer research |
container_volume | 16 |
creator | RAVICHANDRAN, Kameswaran VELMURUGAN, Balaiya GU, Mallikarjuna SINGH, Rana P AGARWAL, Rajesh |
description | Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice.
Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis.
Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P < 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P < 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P < 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin.
Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention. |
doi_str_mv | 10.1158/1078-0432.ccr-10-1213 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3000041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20823143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</originalsourceid><addsrcrecordid>eNpVkM1OGzEUhS1UBBR4BCpvWE7iO7bHkw1SNII2CITEz4qF5fHYiauJjexJ1fD0dYAEeje-Oj7nXOlD6AzICIDXYyCiLgij5UjrWAApoAS6h46Ac1HQsuLf8r71HKLvKf0mBBgQdoAOS1KXFBg9Qs8zv3CtG0Jc40trjR5wsPjB9Vn0zmM1V86nAU9fw9_10gwL5U0x891Kmw43oQ8eP66WIbq58Sa5hHNmOr7Gt06bE7RvVZ_M6cd7jJ6uLh-bX8XN3c9ZM70pNOf1UAg6EYy2olVWmEpVRFSEdrZsOenERAPXhpUVCG5aOxEKsspYR0Rbt1bTWtBjdPHe-7Jql6bTxg9R9fIluqWKaxmUk___eLeQ8_BHUpKHQS7g7wU6hpSisbssELmhLTck5YakbJr7NzXTzrkfXw_vUlu82XD-YVBJq95G5bVLnz5aMiEqoP8AyhiJtQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>RAVICHANDRAN, Kameswaran ; VELMURUGAN, Balaiya ; GU, Mallikarjuna ; SINGH, Rana P ; AGARWAL, Rajesh</creator><creatorcontrib>RAVICHANDRAN, Kameswaran ; VELMURUGAN, Balaiya ; GU, Mallikarjuna ; SINGH, Rana P ; AGARWAL, Rajesh</creatorcontrib><description>Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice.
Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis.
Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P < 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P < 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P < 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin.
Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-10-1213</identifier><identifier>PMID: 20823143</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Angiogenic Proteins - metabolism ; Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Apoptosis - drug effects ; Azoxymethane ; Biological and medical sciences ; Carcinogens ; Carcinoma - chemically induced ; Carcinoma - pathology ; Carcinoma - prevention & control ; Cell Proliferation - drug effects ; Colonic Neoplasms - chemically induced ; Colonic Neoplasms - pathology ; Colonic Neoplasms - prevention & control ; Cytoprotection - drug effects ; Dose-Response Relationship, Drug ; Down-Regulation - drug effects ; Drug Evaluation, Preclinical ; Inflammation Mediators - metabolism ; Male ; Medical sciences ; Mice ; Mice, Inbred Strains ; Pharmacology. Drug treatments ; Silymarin - pharmacology ; Silymarin - therapeutic use</subject><ispartof>Clinical cancer research, 2010-09, Vol.16 (18), p.4595-4606</ispartof><rights>2015 INIST-CNRS</rights><rights>2010 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</citedby><cites>FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23247761$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20823143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RAVICHANDRAN, Kameswaran</creatorcontrib><creatorcontrib>VELMURUGAN, Balaiya</creatorcontrib><creatorcontrib>GU, Mallikarjuna</creatorcontrib><creatorcontrib>SINGH, Rana P</creatorcontrib><creatorcontrib>AGARWAL, Rajesh</creatorcontrib><title>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice.
Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis.
Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P < 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P < 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P < 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin.
Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.</description><subject>Angiogenic Proteins - metabolism</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Azoxymethane</subject><subject>Biological and medical sciences</subject><subject>Carcinogens</subject><subject>Carcinoma - chemically induced</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - prevention & control</subject><subject>Cell Proliferation - drug effects</subject><subject>Colonic Neoplasms - chemically induced</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - prevention & control</subject><subject>Cytoprotection - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Down-Regulation - drug effects</subject><subject>Drug Evaluation, Preclinical</subject><subject>Inflammation Mediators - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Pharmacology. Drug treatments</subject><subject>Silymarin - pharmacology</subject><subject>Silymarin - therapeutic use</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkM1OGzEUhS1UBBR4BCpvWE7iO7bHkw1SNII2CITEz4qF5fHYiauJjexJ1fD0dYAEeje-Oj7nXOlD6AzICIDXYyCiLgij5UjrWAApoAS6h46Ac1HQsuLf8r71HKLvKf0mBBgQdoAOS1KXFBg9Qs8zv3CtG0Jc40trjR5wsPjB9Vn0zmM1V86nAU9fw9_10gwL5U0x891Kmw43oQ8eP66WIbq58Sa5hHNmOr7Gt06bE7RvVZ_M6cd7jJ6uLh-bX8XN3c9ZM70pNOf1UAg6EYy2olVWmEpVRFSEdrZsOenERAPXhpUVCG5aOxEKsspYR0Rbt1bTWtBjdPHe-7Jql6bTxg9R9fIluqWKaxmUk___eLeQ8_BHUpKHQS7g7wU6hpSisbssELmhLTck5YakbJr7NzXTzrkfXw_vUlu82XD-YVBJq95G5bVLnz5aMiEqoP8AyhiJtQ</recordid><startdate>20100915</startdate><enddate>20100915</enddate><creator>RAVICHANDRAN, Kameswaran</creator><creator>VELMURUGAN, Balaiya</creator><creator>GU, Mallikarjuna</creator><creator>SINGH, Rana P</creator><creator>AGARWAL, Rajesh</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20100915</creationdate><title>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</title><author>RAVICHANDRAN, Kameswaran ; VELMURUGAN, Balaiya ; GU, Mallikarjuna ; SINGH, Rana P ; AGARWAL, Rajesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c558t-739743b7baf7e6a607603df2b50d79c15ce426175ebf97a10d744d07b8bfc3873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Angiogenic Proteins - metabolism</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Azoxymethane</topic><topic>Biological and medical sciences</topic><topic>Carcinogens</topic><topic>Carcinoma - chemically induced</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - prevention & control</topic><topic>Cell Proliferation - drug effects</topic><topic>Colonic Neoplasms - chemically induced</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - prevention & control</topic><topic>Cytoprotection - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Down-Regulation - drug effects</topic><topic>Drug Evaluation, Preclinical</topic><topic>Inflammation Mediators - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Pharmacology. Drug treatments</topic><topic>Silymarin - pharmacology</topic><topic>Silymarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RAVICHANDRAN, Kameswaran</creatorcontrib><creatorcontrib>VELMURUGAN, Balaiya</creatorcontrib><creatorcontrib>GU, Mallikarjuna</creatorcontrib><creatorcontrib>SINGH, Rana P</creatorcontrib><creatorcontrib>AGARWAL, Rajesh</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RAVICHANDRAN, Kameswaran</au><au>VELMURUGAN, Balaiya</au><au>GU, Mallikarjuna</au><au>SINGH, Rana P</au><au>AGARWAL, Rajesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2010-09-15</date><risdate>2010</risdate><volume>16</volume><issue>18</issue><spage>4595</spage><epage>4606</epage><pages>4595-4606</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>Colorectal cancer is the second leading cause of cancer-associated deaths, which suggests that more effort is needed to prevent/control this disease. Herein, for the first time, we investigate in vivo the efficacy of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice.
Five-week-old male mice were gavaged with vehicle or silibinin (250 and 750 mg/kg) for 25 weeks starting 2 weeks before initiation with azoxymethane (pretreatment regime) or for 16 weeks starting 2 weeks after the last azoxymethane injection (posttreatment regime). The mice were then sacrificed, and colon tissues were examined for tumor multiplicity and size, and molecular markers for proliferation, apoptosis, inflammation, and angiogenesis.
Silibinin feeding showed a dose-dependent decrease in azoxymethane-induced colon tumorigenesis with stronger efficacy in pretreatment versus posttreatment regimen. Mechanistic studies in tissue samples showed that silibinin inhibits cell proliferation as evident by a decrease (P < 0.001) in proliferating cell nuclear antigen and cyclin D1, and increased Cip1/p21 levels. Silibinin also decreased (P < 0.001) the levels of inducible nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor, suggesting its anti-inflammatory and antiangiogenic potential in this model. Further, silibinin increased cleaved caspase-3 and poly(ADP-ribose) polymerase levels, indicating its apoptotic effect. In other studies, colonic mucosa and tumors expressed high levels of β-catenin, insulin-like growth factor-1 receptorβ, phospho Glycogen synthase kinase-3β, and phospho protein kinase B/pAkt proteins in azoxymethane-treated mice, which were strongly lowered (P < 0.001) by silibinin treatment. Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin.
Silibinin targets β-catenin and IGF-1Rβ pathways for its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in A/J mice. Overall, these results support the translational potential of silibinin in colorectal cancer chemoprevention.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>20823143</pmid><doi>10.1158/1078-0432.ccr-10-1213</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1078-0432 |
ispartof | Clinical cancer research, 2010-09, Vol.16 (18), p.4595-4606 |
issn | 1078-0432 1557-3265 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3000041 |
source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Angiogenic Proteins - metabolism Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antioxidants - pharmacology Antioxidants - therapeutic use Apoptosis - drug effects Azoxymethane Biological and medical sciences Carcinogens Carcinoma - chemically induced Carcinoma - pathology Carcinoma - prevention & control Cell Proliferation - drug effects Colonic Neoplasms - chemically induced Colonic Neoplasms - pathology Colonic Neoplasms - prevention & control Cytoprotection - drug effects Dose-Response Relationship, Drug Down-Regulation - drug effects Drug Evaluation, Preclinical Inflammation Mediators - metabolism Male Medical sciences Mice Mice, Inbred Strains Pharmacology. Drug treatments Silymarin - pharmacology Silymarin - therapeutic use |
title | Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A57%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibitory%20Effect%20of%20Silibinin%20against%20Azoxymethane-Induced%20Colon%20Tumorigenesis%20in%20A/J%20Mice&rft.jtitle=Clinical%20cancer%20research&rft.au=RAVICHANDRAN,%20Kameswaran&rft.date=2010-09-15&rft.volume=16&rft.issue=18&rft.spage=4595&rft.epage=4606&rft.pages=4595-4606&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.ccr-10-1213&rft_dat=%3Cpubmed_cross%3E20823143%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20823143&rfr_iscdi=true |